Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Center of Excellence in Biomechanics and Innovative Spine Surgery, Chulalongkorn University, Bangkok, Thailand; Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Orthopedic Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
World Neurosurg. 2023 Jul;175:e662-e668. doi: 10.1016/j.wneu.2023.04.003. Epub 2023 Apr 7.
This study evaluated the effect of prolonged concordant response and functional clinical improvement between lidocaine and bupivacaine for cervical medial branch block (CMBB) in chronic cervical facet syndrome.
Sixty-two patients diagnosed with chronic cervical facet syndrome were randomized into either lidocaine or bupivacaine groups. The therapeutic CMBB was performed under ultrasound guidance. Either 2% lidocaine or 0.5% bupivacaine with a volume of 0.5-1 mL per level was injected according to the patient's pain symptoms. The patients, pain assessor, and pain specialist were blinded. The primary outcome was the duration of pain reduction by at least 50%. The Numerical Rating Scale of 0-10 and the Neck Disability Index questionnaire were recorded.
There was no significant difference in the duration of 50% and 75% pain reduction and Neck Disability Index between the lidocaine and bupivacaine groups. Lidocaine provided significant pain reduction up to 16 weeks (P < 0.05) and significant improvement in neck functional outcomes up to 8 weeks (P < 0.01) compared to the baseline. While bupivacaine yielded significant pain alleviation for up to 8 weeks for pain upon neck mobilization (P < 0.05) and demonstrated notable improvement in neck function up to 4 weeks (P < 0.01) compared to the baseline.
CMBB using lidocaine or bupivacaine provided clinical benefits in prolonged analgesic effect and improving neck functions for chronic cervical facet syndrome. Lidocaine illustrated better performance and could be considered a local anesthetic of choice regarding the prolonged concordance response.
本研究评估了利多卡因和布比卡因在慢性颈脊神经后支阻滞(CMBB)中对颈脊神经后支阻滞(CMBB)的延长一致性反应和功能临床改善的效果,用于治疗慢性颈脊神经后支综合征。
62 例慢性颈脊神经后支综合征患者随机分为利多卡因组或布比卡因组。在超声引导下进行治疗性 CMBB。根据患者的疼痛症状,每级注射 2%利多卡因或 0.5%布比卡因,容量为 0.5-1 毫升。患者、疼痛评估者和疼痛专家均不知情。主要结局是疼痛减轻至少 50%的持续时间。记录数字评分量表(0-10 分)和颈部残疾指数问卷。
利多卡因和布比卡因组在 50%和 75%疼痛缓解和颈部残疾指数的持续时间上无显著差异。与基线相比,利多卡因组在 16 周时(P < 0.05)显著减轻疼痛,在 8 周时(P < 0.01)显著改善颈部功能结果;而布比卡因组在 8 周时(P < 0.05)对颈部活动时的疼痛有显著的镇痛作用,在 4 周时(P < 0.01)对颈部功能有显著的改善。
CMBB 使用利多卡因或布比卡因可提供延长的镇痛效果和改善慢性颈脊神经后支综合征颈部功能的临床益处。利多卡因表现出更好的性能,并且可以考虑作为一种局部麻醉剂,用于延长一致性反应。